Corrigendum to “Selective Progesterone Receptor Modulators for the Medical Treatment of Uterine Fibroids with a Focus on Ulipristal Acetate”

In the article titled “Selective Progesterone Receptor Modulators for the Medical Treatment of Uterine Fibroids with a Focus on Ulipristal Acetate” [1], the affiliation of the third author was incorrect. The corrected affiliation is shown above. In addition, the Conflicts of Interest section should be updated as follows:

The authors have each previously received financial support from Gedeon Richter, who market ulipristal acetate as ESMYA®. Thomas Rabe received fees for lectures, publications, and participation on the advisory board before retiring in 2016, Thomas Roemer received fees for lectures and consultancy work, Nicole Sänger has been a consultant for Gedeon Richter and has received travel expenses and lecture fees, Hans-Rudolf Tinneberg received fees for lectures, Andreas D. Ebert received financial support for lectures and the establishment of the Myom-Netwerk, Markus Wallwiener received a honorarium for a congress presentation, and Rudy Leon De Wilde was reimbursed for costs concerning a presentation on myoma surgery.